Northwest Biotherapeutics Inc (OTC: NWBO)

Sector: Healthcare Industry: Biotechnology CIK: 0001072379
P/B -3.22
P/E -3.83
P/S 373.20
Market Cap 349.69 Mn
ROIC (Qtr) 208.77
Div Yield % 0.00
Rev 1y % (Qtr) -43.98
Total Debt (Qtr) 77.05 Mn
Debt/Equity (Qtr) -0.71

About

Stock Price Chart

Analysis

Pros

  • Retained earnings of (1.51B) represent substantial 13.85x of equity (108.65M), indicating strong internal capital generation.
  • Cash reserves of 4.56M provide solid 2.68x coverage of other non-current liabilities 1.70M, indicating strong liquidity.
  • Robust R&D investment of 33.75M at 1.05x of SG&A 32.09M demonstrates strong commitment to innovation and future growth.
  • Strong R&D investment of 33.75M at 49.86x of capex 677000 shows balanced investment in innovation and infrastructure.
  • Strong tangible asset base of 28.69M provides 14.96x coverage of intangibles 1.92M, indicating robust asset quality.

Cons

  • Investment activities of (988000) provide weak support for R&D spending of 33.75M, which is -0.03x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Free cash flow of (50.86M) provides weak coverage of capital expenditures of 677000, with a -75.12 ratio suggesting additional external financing needs for growth initiatives.
  • The company's operating cash flow of (50.18M) shows concerning coverage of stock compensation expenses of 1.48M, with a -34 ratio indicating potential earnings quality issues.
  • Operating earnings of (81.24M) show weak coverage of depreciation charges of 2.04M, with a -39.88 ratio indicating high capital intensity and potential reinvestment needs.
  • Free cash flow of (50.86M) represents just -1.69x of debt issuance 30.13M, suggesting concerning reliance on leverage rather than internal cash generation for growth.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 13.56 12.31
EV to Cash from Ops. -8.27 23.25
EV to Debt 5.39 738.44
EV to EBIT -5.11 -9.16
EV to EBITDA -6.60 6.95
EV to Free Cash Flow [EV/FCF] -8.16 21.90
EV to Market Cap 1.19 65.67
EV to Revenue 443.10 227.32
Price to Book Value [P/B] -3.22 22.34
Price to Earnings [P/E] -3.83 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio -62.87 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -9.52 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 50.00 -27.13
Cash and Equivalents Growth (1y) % 55.15 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -28.92 -46.93
EBITDA Growth (1y) % -2.75 -1.68
EBIT Growth (1y) % -28.92 -56.45
EBT Growth (1y) % -29.11 -12.70
EPS Growth (1y) % 14.29 -28.31
FCF Growth (1y) % 7.78 -31.90
Gross Profit Growth (1y) % -41.29 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.03 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 0.05 3.85
Current Ratio 0.08 7.27
Debt to Equity Ratio -0.71 0.40
Interest Cover Ratio -9.52 841.00
Times Interest Earned -9.52 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -8,452.40 -18,234.31
EBIT Margin % -8,669.80 -18,580.80
EBT Margin % -9,580.90 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % -9,735.80 -19,439.22